PAREXEL International Corporation (NASDAQ:PRXL) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
PAREXEL International Corporation, will be presenting at the JP
Morgan Healthcare Conference in San Francisco at 4:00 p.m. PT on
January 10, 2017. Slides 15 and 17 of his presentation will
include certain information regarding the quarter ended December
31, 2016, which slides are furnished herewith as Exhibit 99.1. A
live webcast of the presentation will be available through the
Investors section of PAREXELs website at www.PAREXEL.com in the
Upcoming Events portion of the main page, and a replay of the
presentation will be available on the website for 90 days after
the presentation.
not be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934 (the Exchange Act) or otherwise subject to
the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such a filing.
|
Exhibit No.
|
Description
|
|
99.1
|
Slides 15 and 17 of Presentation of PAREXEL
International Corporation at the JP Morgan Healthcare Conference, dated January 10, 2017. |
About PAREXEL International Corporation (NASDAQ:PRXL)
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries. Its segments include Clinical Research Services (CRS), PAREXEL Consulting Services (PC) and PAREXEL Informatics (PI). The CRS segment includes various phases of clinical research from first-in-man trials, where a medicinal entity is tested on human subjects for the first time, through post-marketing studies, following approval by the presiding regulatory body. The PC segment provides technical expertise and advice in areas, such as strategy, drug development, regulatory affairs, strategic compliance and targeted communications services in support of product launch. The Company’s PI segment provides information technology solutions. PAREXEL International Corporation (NASDAQ:PRXL) Recent Trading Information
PAREXEL International Corporation (NASDAQ:PRXL) closed its last trading session up +0.21 at 68.50 with 937,782 shares trading hands.